ACTRN12622000864729暂停未知
A pre-, post-intervention and 3-month follow up open trial to evaluate the effect of the BDZ digital health program on benzodiazepine usage, anxiety and depressive symptoms, and hope in Australian adults using benzodiazepines
Federation University0 个研究点目标入组 52 人开始时间: 2022年6月17日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 暂停
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Participants must be 18 years or older, currently using benzodiazepines, have access to the internet, provide consent, and be able to register online using an email address.
排除标准
- •Participants must not be residing overseas, do not have a current untreated and severe (psychotic) illness, nor will they be using the ‘cold turkey’ method to reduce their benzodiazepine intake during the study (i.e., complete withdrawal from their benzodiazepines).
研究者
相似试验
终止
不适用
An open trial evaluation of the BDZ (information and reduction) digital health program for people using benzodiazepines.Benzodiazepine dependencyMental Health - AddictionMental Health - AnxietyACTRN12617000574347Federation University49
进行中（未招募）
1 期
A randomized phase III study of follow up with or without adjuvant Gefitinib(IressaTM) following chemotherapy in patients with advanced non-small cell lungcancerAdvanced Non Small Cell Lung CarcinomaMedDRA version: 9.1Level: LLTClassification code 10061873Term: Non-small cell lung cancerEUCTR2004-001331-36-GBEuropean Organisation for Research and Treatment of Cancer
尚未招募
不适用
The therapeutic effect of an intrathecal opioid after lumbar interbody fusion surgeryDegenerative lumber diseaseJPRN-UMIN000042077Akita Kousei Medical Center Department of Orthopedic Surgery100
进行中（未招募）
1 期
A randomized phase III study of follow-up with or without Gefitinib (IressaTM) following chemotherapy in patients with advanced non-small cell lung cancer.on small cell lung cancer, advanced.MedDRA version: 6.1Level: PTClassification code 10061873EUCTR2004-001331-36-ITIST. DI RICERCHE FARMACOLOG. M. NEGRI
进行中（未招募）
不适用
A phase III long-term follow-up study to assess the immune responses following vaccination at 36-46 months of age with a booster dose of GSK Biologicals’ 10-valent pneumococcal conjugate vaccine (10Pn-PD-DiT) and to evaluate the immunogenicity and safety of a 2-dose catch-up immunization course with the 10Pn-PD-DiT vaccine in the fourth year of life. - 10PN-PD-DIT-046 EXT:002 Y2A booster vaccination study against Streptococcus pneumoniae in subjects aged 36-46 months and a two-dose vaccination against Streptococcus pneumoniae of age-matched unprimed children.EUCTR2008-003950-14-SEGlaxoSmithKline Biologicals210